Finance
Finance
MwanzoGBT • EPA
Guerbet SA
€ 14.74
21 Okt, 01:49:12 GMT +2 · EUR · EPA · Kanusho
HisaHisa zinazouzwa FR
Bei iliyotangulia
€ 14.58
Bei za siku
€ 14.30 - € 15.16
Bei za mwaka
€ 12.72 - € 39.35
Thamani ya kampuni katika soko
192.25M EUR
Wastani wa hisa zilizouzwa
elfu 41.05
Uwiano wa bei na mapato
36.27
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(EUR)Jun 2025Mabadiliko Tangu Mwaka Uliopita
Mapato
197.36M-7.11%
Matumizi ya uendeshaji wa biashara
149.62M-3.00%
Mapato halisi
1.32M-76.01%
Kiwango cha faida halisi
0.67-74.03%
Mapato kwa kila hisa
EBITDA
22.20M-26.51%
Asilimia ya kodi ya mapato
50.97%
Jumla ya mali
Jumla ya dhima
(EUR)Jun 2025Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
50.12M28.36%
Jumla ya mali
1.02B-2.39%
Jumla ya dhima
644.94M-1.44%
Jumla ya hisa
372.13M
hisa zilizosalia
12.60M
Uwiano wa bei na thamani
0.49
Faida inayotokana na mali
1.84%
Faida inayotokana mtaji
2.42%
Mabadiliko halisi ya pesa taslimu
(EUR)Jun 2025Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
1.32M-76.01%
Pesa kutokana na shughuli
11.27M121.77%
Pesa kutokana na uwekezaji
-7.74M34.85%
Pesa kutokana na ufadhili
-2.44M-335.94%
Mabadiliko halisi ya pesa taslimu
elfu -123.5097.98%
Mtiririko huru wa pesa
14.24M44.21%
Kuhusu
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent. In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index. In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015. In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories. An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1926
Wafanyakazi
2,842
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Watu pia hutafuta
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu